Suppr超能文献

凝血酶的亮氨酸99在决定丝氨酸蛋白酶抑制剂P2特异性中的作用。

Role of Leu99 of thrombin in determining the P2 specificity of serpins.

作者信息

Rezaie A R

机构信息

Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City 73104, USA.

出版信息

Biochemistry. 1997 Jun 17;36(24):7437-46. doi: 10.1021/bi962965u.

Abstract

A recent study indicated that Tyr99 (chymotrypsin numbering) of factor Xa and Thr99 of activated protein C are S2 subsite residues that determine the P2 specificity of their substrates and inhibitors. To investigate the contribution of Leu99 to the P2 binding specificity of thrombin, three mutants of thrombin were prepared in which Leu99 was substituted with Tyr (L99Y), Thr (L99T), or Gly (L99G). Kinetic analysis indicated that antithrombin (AT with P2 Gly) inhibited thrombin L99Y, 14.1- and 5.5-fold slower than thrombin in the absence and presence of heparin, respectively. The L99Y mutation increased the stoichiometry of AT inhibition in the presence of heparin from approximately 1.6 to approximately 4.6, indicating that L99Y recognized AT as a substrate. The inhibition rates of L99T and L99G by AT, respectively, were 500.0- and 916.7-fold slower than thrombin in the absence of heparin but only 41.8- and 64.5-fold slower than thrombin in the presence of heparin. Resolution of the two-step reactions of AT with the mutant thrombins revealed that the impaired reactivities occurred in the second reaction step in which a non-covalent AT-thrombin encounter complex is converted to a stable, covalent complex. In reactions with protein C inhibitor (PCI with P2 Phe), L99Y was inhibited 3.5-fold slower than thrombin, L99T was inhibited at a similar or faster rate, and L99G was inhibited 23.9-fold faster than thrombin. The epidermal growth factor-like domains 4-6 of thrombomodulin (TM4-6) accelerated the PCI inhibition of wild-type and L99G thrombins 73.9- and 5.3-fold, respectively. Further studies indicated that the fibrinogen clotting and protein C activation rates by the mutants were impaired, but the cofactor function of TM was not affected as TM4-6 bound to wild-type [Kd(app) = 5.9 nM] and mutant thrombins with similar affinities [Kd(app) = 4.4-6.9 nM] and enhanced protein C activation rates by all mutants effectively. These results indicate that (1) Leu99 of thrombin is critical for determination of the P2 specificity of serpins, AT and PCI, (2) increasing the polarity of the S2 pocket of thrombin by introduction of a hydrophilic residue into this pocket is detrimental for reaction with AT, but it is tolerated in reaction with PCI, so that only the size of the S2 pocket of thrombin determines the P2 specificity of PCI, and (3) the thrombomodulin-induced conformational change that results in acceleration of thrombin inhibition by PCI involves Leu99.

摘要

最近的一项研究表明,凝血因子Xa的Tyr99(胰凝乳蛋白酶编号)和活化蛋白C的Thr99是S2亚位点残基,它们决定了其底物和抑制剂的P2特异性。为了研究Leu99对凝血酶P2结合特异性的贡献,制备了三种凝血酶突变体,其中Leu99被Tyr(L99Y)、Thr(L99T)或Gly(L99G)取代。动力学分析表明,抗凝血酶(P2为Gly的AT)抑制凝血酶L99Y的速度分别比无肝素和有肝素时的凝血酶慢14.1倍和5.5倍。L99Y突变使有肝素存在时AT抑制的化学计量比从约1.6增加到约4.6,表明L99Y将AT识别为底物。在无肝素时,AT对L99T和L99G的抑制率分别比凝血酶慢500.0倍和916.7倍,但在有肝素时仅比凝血酶慢41.8倍和64.5倍。对AT与突变凝血酶两步反应的解析表明,反应活性受损发生在第二步反应中,即非共价的AT - 凝血酶相遇复合物转化为稳定的共价复合物。在与蛋白C抑制剂(P2为Phe的PCI)反应时,L99Y被抑制的速度比凝血酶慢3.5倍,L99T被抑制的速度相似或更快,而L99G被抑制的速度比凝血酶快23.9倍。血栓调节蛋白的表皮生长因子样结构域4 - 6(TM4 - 6)分别使野生型和L99G凝血酶的PCI抑制加速73.9倍和5.3倍。进一步研究表明,突变体的纤维蛋白原凝血和蛋白C活化率受损,但TM的辅因子功能未受影响,因为TM4 - 6以相似的亲和力(野生型的Kd(app) = 5.9 nM,突变凝血酶的Kd(app) = 4.4 - 6.9 nM)与野生型和突变凝血酶结合,并有效提高了所有突变体的蛋白C活化率。这些结果表明:(1)凝血酶的Leu99对于确定丝氨酸蛋白酶抑制剂AT和PCI的P2特异性至关重要;(2)通过在该口袋中引入亲水性残基来增加凝血酶S2口袋的极性对与AT的反应不利,但在与PCI的反应中是可耐受的,因此只有凝血酶S2口袋的大小决定PCI的P2特异性;(3)血栓调节蛋白诱导的构象变化导致PCI对凝血酶抑制的加速涉及Leu99。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验